Diabetic Nephropathy | Current Treatment: Physician Insights | US | 2017
Diabetic nephropathy (DN) refers to kidney disease caused by diabetes. DN is a leading cause of chronic kidney disease (CKD), and is associated with high morbidity, mortality, and cost. Use of pharmacotherapy for DN varies by disease severity, physician specialty, and CKD stage. Physicians consider management of DN challenging because current therapies manage only the complications of DN. Currently available therapies have limited efficacy, are unable to treat the underlying disease, and prevent progressive renal decline in patients. Our Current Treatment deep dive content investigates the current prescribing practices for DN and focuses on the various factors driving the these treatment decisions.
Questions Answered
- Do treatment decisions for DN differ based on disease progression and the specialty of the treating physician?
- Which attributes are most important in choosing drugs for the management of DN patients?
- How do physicians perceive standard of care therapies such as ACE inhibitors or ARBs for DN?
- What is the level of satisfaction among physicians with currently available DN treatments? What is the level of familiarity and interest in products in the development pipeline?
Related Market Assessment Reports
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
